New pill targets virus to shrink Hard-to-Treat throat cancer
NCT ID NCT04925544
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 29 times
Summary
This study tests an experimental pill, VK 2019, that blocks a key protein (EBNA1) used by the Epstein-Barr virus to drive cancer growth. It is for 13 adults with advanced nasopharyngeal cancer that is linked to EBV and has not responded to other treatments. The main goal is to see if the drug can shrink tumors or slow the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.